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Abstract
Alzheimer’s disease (AD) is often characterized by the impairment of mitochondrial function caused by excessive
mitochondrial fragmentation. Thrombospondin-1 (TSP-1), which is primarily secreted from astrocytes in the central
nervous system (CNS), has been suggested to play a role in synaptogenesis, spine morphology, and synaptic density of
neurons. In this study, we investigate the protective role of TSP-1 in the recovery of mitochondrial morphology and
function in amyloid β (Aβ)-treated mouse hippocampal neuroblastoma cells (HT22). We observe that TSP-1 inhibits Aβ-
induced mitochondrial fission by maintaining phosphorylated-Drp1 (p-Drp1) levels, which results in reduced Drp1
translocation to the mitochondria. By using gabapentin, a drug that antagonizes the interaction between TSP-1 and its
neuronal receptor α2δ1, we observe that α2δ1 acts as one of the target receptors for TSP-1, and blocks the reduction
of the p-Drp1 to Drp1 ratio, in the presence of Aβ. Taken together, TSP-1 appears to contribute to maintaining the
balance in mitochondrial dynamics and mitochondrial functions, which is crucial for neuronal cell viability. These data
suggest that TSP-1 may be a potential therapeutic target for AD.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative dis-
order characterized by senile plaques, neurofibrillary
tangles, mitochondrial dysfunction, and neuronal cell
death1. Previous studies have reported that the amyloid β
(Aβ) proteins are responsible for mitochondrial impair-
ment during disease progression2. Moreover, mitochon-
drial accumulation of Aβ is directly associated with
neuronal toxicity, which can contribute to neuronal cell
death in AD3.
Mitochondrial function is crucial for cell survival. The
mitochondria are responsible for ATP production
through oxidative phosphorylation (OXPHOS), conduc-
tion of signals, and regulation of programmed cell death4.
At the same time, mitochondria are highly dynamic
organelles that undergo fission, fusion, transportation,
and autophagy-mediated mitochondrial degradation.
Thus, balanced mitochondrial dynamics is essential for
maintaining mitochondrial function and cell survival.
Mitochondrial fission/fusion is one of the major compo-
nents of mitochondrial quality control5. Several mito-
chondrial fission/fusion proteins have previously been
discovered. Mitofusin 1 and 2 (Mfn1 and 2), as well as
optic atrophy type 1 (OPA1) induce mitochondrial fusion,
while dynamin-related protein-1 (Drp1) and mitochon-
drial fission 1 protein (Fis1) participate in mitochondrial
fission6. Disruption of mitochondrial morphology and
subsequent mitochondrial dysfunctions have often been
observed in the brains of both AD patients and experi-
mental model animals3,7,8. In addition, several previous
studies on AD have also reported alterations in post-
translational modification (PTM) or activity of Drp1,
which is a mitochondrial fission protein9,10.
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Thrombospondins (TSPs) are large oligomeric extra-
cellular matrix proteins that are mainly secreted from
astrocytes. TSPs play a major role in synaptogenesis, cell
migration, and angiogenesis11. TSP family members are
subdivided according to their organization and domain
structure. TSP-1 and TSP-2 are assembled as trimers,
whereas TSP-3, TSP-4, and TSP-5 are assembled as penta-
mers12. All isoforms are expressed in the brain, however, a
study using purified retinal ganglion cells demonstrated that
TSP-1 and TSP-2 are especially important in facilitating
excitatory synapse formation11. Eroglu et al.13 found that the
synaptogenic activity of TSPs is mapped into their epidermal
growth factor (EGF)-like repeat domain. In addition, the
EGF-like repeats of TSPs bind to the von Willebrand factor
A (VWF-A)-like domain of α2δ1, the non-pore-forming
auxiliary subunit of a voltage-gated calcium channel
(VGCC) highly expressed in brain14,15. Furthermore, α2δ1
has been reported as a neuronal receptor of TSP, which
regulates excitatory synaptogenesis in the central nervous
system (CNS)14. Thus, in terms of the synaptogenic effect of
TSPs, the interaction of TSP-α2δ1 may be crucial to neu-
ronal function although the downstream signaling of α2δ1
has not been fully identified yet. Due to the ability of TSP-1
and TSP-2 to promote the formation of new synapses,
several studies have investigated the protective role of TSP-1
and TSP-2 in the context of brain injuries and neurode-
generative diseases, such as in stroke and AD, respectively.
The expression of both TSP-1 and TSP-2 is significantly
increased after stroke, and this upregulation of TSP-1 and 2
was mainly due to the enhanced purinergic signaling in
astrocytes16. In addition, using TSP-1/2 double knockout
mice, it has been reported that synapse formation and
axonal outgrowth are largely supported by TSP-1/2 after
stroke17. In an AD study, Son and colleagues found that the
amount of TSP-1 secreted from astrocytes is decreased in
Aβ-treated U373MG human astroglioma cells, the brains of
AD model mice, and in human AD postmortem brains.
Interestingly, the intrasubicular injection of TSP-1 into AD
model mouse brains attenuated the Aβ-induced down-
regulation of synaptic proteins and reduction of functional
synaptic activity, suggesting that TSP-1 has a protective
effect on AD pathogenesis18.
Synaptic loss and mitochondrial damage occur during
the early period of AD pathogenesis, suggesting that these
prominent features of early AD are primary events for AD
progression19,20. In addition, synaptic deficit has been
known to be closely associated with mitochondrial dys-
function21, and these pathological characteristics of AD
are correlated with cognitive impairment22. Many lines of
evidence have suggested a close association between
synaptic dysfunction and mitochondrial disruption. For
instance, damaged mitochondria accumulate in neuronal
cell bodies in postmortem brains of AD patients23. In line
with this report, impaired mitochondrial trafficking and
synaptic deficit due to Aβ treatment in hippocampal
neurons have been reported24,25. Furthermore, Gillardon
et al.26 found accumulated Aβ and downregulated energy
metabolism in the synaptosomal mitochondrial fraction of
AD transgenic mice, indicating that Aβ may be a crucial
causative factor in mitochondrial dysfunction and the
subsequent synaptic deficit and loss. However, specific
mechanisms and molecules associated with this phe-
nomenon have not been fully elucidated yet.
In this study, we present evidence of the protective role
of TSP-1, in the Aβ-induced disruption of mitochondrial
morphology and impairment mitochondrial functions
using the HT22 mouse hippocampal neuronal cell line.
Treatment of the cells with TSP-1 human recombinant
protein blocked Aβ-induced excessive mitochondrial fis-
sion by maintaining the relative ratio of p-Drp1 to Drp1
protein at a level similar to that observed under normal
conditions. Consistently, co-treatment with TSP-1 pre-
vented Aβ-induced mitochondrial dysfunctions such as
decreased ATP production and neuronal cell death. Fur-
thermore, by blocking the interaction between TSP-1 and
its neuronal receptor α2δ1, we also showed that α2δ1 may
act as one of the target receptors of TSP-1, facilitating the
protective effects of TSP-1 against Aβ-induced mito-
chondrial impairment in HT22 cells. Thus, our study
suggests that TSP-1 may be a potential therapeutic target
for AD drug development with respect to mitochondrial
morphology and functions.
Results
TSP-1 inhibits Aβ-induced mitochondrial fission in HT22
cells
Due to the correlation between mitochondrial dys-
function and synaptic deficit in the context of AD
pathology19–21, we first investigated whether TSP-1 has a
role not only in synaptogenesis as previously reported11,18
but also in mitochondrial functions during AD patho-
genesis. Balanced mitochondrial dynamics between fission
and fusion is one of the most important mechanisms for
keeping mitochondrial quality control. Thus, we checked
whether TSP-1 can affect mitochondrial morphology.
HT22 cells were pretreated with human TSP-1 recombi-
nant protein (500 ng/ml) for 1 h and then dimethylsulf-
oxide (DMSO) or Aβ (1 μM) was added to the medium
and incubated for the next 23 h. To check mitochondrial
morphology using the confocal microscope, HT22 cells
were stained with MitoTracker Green FM and images
were obtained from vehicle-, Aβ alone-, Aβ+TSP-1-, and
TSP-1 alone-treated groups (Fig. 1a). Through Image J
analysis of mitochondrial morphology using an index of
aspect ratio and form factor (Fig. 1b, c), we observed that
treatment with TSP-1 protein can block the Aβ-induced
mitochondrial fission. To further confirm the protective
role of TSP-1 in mitochondrial morphology, we analyzed
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the mitochondrial morphology of the same groups using
electron microscopy (EM) (Fig. 1d). TSP-1 treatment
completely rescued the Aβ-induced shortening of mito-
chondrial length, which is a characteristic of mitochon-
drial fission (Fig. 1e). In addition, TSP-1 also rescued the
Aβ-induced increase in the damaged mitochondria frac-
tion, which is shown as the white-colored part in the EM
image due to the void content of mitochondria (Fig. 1f).
Finally, TSP-1 also blocked the increase in the number of
mitochondria per cell in the Aβ-treated group (Fig. 1g).
These data demonstrate that TSP-1 can inhibit Aβ-
induced mitochondrial fission in HT22 cells.
TSP-1 prevents Aβ-mediated mitochondrial dysfunction in
HT22 cells
To investigate whether TSP-1 also restores Aβ-mediated
mitochondrial dysfunction, TSP-1 recombinant protein
was administered to Aβ-treated HT22 cells. To measure
mitochondrial function, we first examined the total
intracellular reactive oxygen species (ROS) and the mito-
chondrial ROS levels using DCFDA and mitoSOX assays,
respectively (Fig. 2a, c). Co-treatment of TSP-1 and Aβ
significantly blocked the increase of both total and mito-
chondrial ROS levels compared to Aβ-treated group
(Fig. 2b, d). In addition, to measure the oxygen con-
sumption rate (OCR) after Aβ treatment, basal respiration,
ATP production, maximal capacity of the OXPHOS sys-
tem, and non-mitochondrial respiration were calculated
(Fig. 2e). Basal respiration, ATP production, and maximal
capacity significantly recovered in the TSP-1- and TSP-1
+Aβ-treated groups compared to the Aβ only-treated
group (Fig. 2f–h). However, non-mitochondrial respiration
was comparable among the vehicle-, Aβ-, TSP-1+Aβ-,
and TSP-1-treated groups (Fig. 2i). Overall, these data
indicate that the TSP-1 protein mitigates Aβ-induced
mitochondrial dysfunction in HT22 cells.
TSP-1 rescues neuronal cell viability against Aβ toxicity in
HT22 cells and primary hippocampal neurons
Since mitochondrial dysfunction caused by excessive
fission leads to intrinsic apoptosis27, we hypothesized that
TSP-1 treatment might inhibit Aβ-induced toxicity and
rescue neuronal cell viability by reducing mitochondrial
fission. To investigate this possibility, we performed MTT,
calcein-AM, and TUNEL assays to check the cell viability
of the vehicle-, Aβ-, Aβ+TSP-1-, and TSP-1-treated
groups (Fig. 3a–c). Decreased cell viabilities of Aβ-treated
groups were fully recovered by TSP-1 treatment in MTT,
calcein-AM (HT22 cells), and TUNEL assays (primary rat
hippocampal neurons). These data show that treatment
with TSP-1 prevents Aβ-induced toxic effects on neuronal
cell survival.
TSP-1 restores Aβ-induced decrease of p-Drp1 to Drp1
ratio
One of the well-known pathological features of AD is
impaired Ca2+ homeostasis1. A previous report shows
that an influx of Ca2+ into neurons causes mitochondrial
fission28. Since Aβ elevates the amount of intracellular
Ca2+ level and causes mitochondrial fission, we investi-
gated whether TSP-1 could block Aβ-mediated mito-
chondrial fission by directly regulating intracellular Ca2+
level. To identify this possibility, a fluo-4 assay was per-
formed to measure the intracellular Ca2+ level in the
vehicle-, Aβ-, Aβ+TSP-1-, and TSP-1-treated groups
(Supplementary Figure 1a). However, TSP-1 treatment
did not restore Aβ-induced intracellular Ca2+ elevation
(Supplementary Figure 1b). Thus, we investigated whether
TSP-1 could regulate mitochondrial fission proteins,
especially Drp1. Drp1 is a key regulatory protein of
mitochondrial fragmentation, and previous reports have
demonstrated that the PTM of Drp1 is important to its
activity in the fission mechanism29. There are various
PTMs of Drp1, however, we focused on the phosphor-
ylation of the Ser637 residue owing to its importance in
both mitochondrial fission and apoptosis30. In addition,
pSer637 Drp1 exists in the cytosol, while depho-
sphorylation of Ser637 Drp1 results in its translocation
into the mitochondria to start the fission process30. To
check the possibility of a regulatory role for TSP-1 on the
level of p-Drp1, a western blot analysis was performed in
cells from the vehicle-, Aβ-, Aβ+TSP-1-, and TSP-1-
(see figure on previous page)
Fig. 1 TSP-1 inhibits Aβ-induced mitochondrial fission in HT22 cells. a HT22 cells were stained with MitoTracker green dye to visualize
mitochondrial morphology. Magnified images in lower panels are the areas marked with white lines. Scale bar, 20 μm. b, c Mitochondrial length,
represented as aspect ratio and mitochondrial circular shape, represented as form factor were analyzed with the Image J program software. TSP-1
treatment significantly recovered Aβ-induced mitochondrial fragmentation. Data were obtained from at least three replicates for each group, and
100–150 cells were analyzed for each group. Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001 vs. vehicle (DMSO)-treated cells; #p < 0.05 vs.
Aβ-treated cells. d The effect of TSP-1 on mitochondrial morphology was analyzed in EM images. Arrows indicate normal mitochondria. Arrow heads
indicate fissioned mitochondria. Dashed circle indicates damaged (void) mitochondria. Scale bar, 1 μm. e–g Average mitochondrial length, number
of damaged (void) mitochondria per one cell, and the total number of mitochondria per one cell were quantified. TSP-1 treatment significantly
recovered mitochondrial length, decreased number of damaged mitochondria, and the total number of mitochondria per one cell. Data were
obtained from at least two replicates, and more than total 10 mitochondria were analyzed for each group. Data are presented as mean ± SEM. **p <
0.01, ***p < 0.001 vs. vehicle (DMSO)-treated cells; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. Aβ-treated cells
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treated groups (Fig. 4a). Interestingly, the Aβ-induced
reduction in the ratio of p-Drp1 to Drp1 proteins was
significantly rescued by TSP-1 treatment (Fig. 4b). How-
ever, there was no alteration in levels of other fission/
fusion proteins, including Mfn1, OPA1, and Fis1 upon
TSP-1 treatment (Fig. 4c–e). These data suggest that TSP-
1 may play a protective role in Aβ-induced mitochondrial
dysfunction and neuronal cell death possibly by main-
taining the ratio of p-Drp1 to Drp1 proteins.
α2δ1 receptor is important to mediate the regulating
effect of TSP-1 for the ratio of p-Drp1 to Drp1
Next, we investigated the possible protective
mechanism of TSP-1 on Aβ-induced mitochondrial dys-
function and reduction of neuronal cell viability.
Several receptors for TSP-1 have been reported including
neuroligin-1 (NL1), CD47, and α2δ131. Out of these, α2δ1
is a neuronal receptor of TSP regulating excitatory
synaptogenesis in the CNS14. Furthermore, we have
previously reported that TSP-1 mitigates Aβ-induced
synaptic dysfunction and reduction of synaptic
proteins via the α2δ1 receptor on neurons18. Thus, the
interaction of TSP-1-α2δ1 may be crucial to neuronal cell
viability, which is directly affected by mitochondrial
function, although the downstream signaling of α2δ1
has not been fully identified yet. Therefore, we examined
whether the α2δ1 receptor, which is highly expressed
in HT22 cells (Supplementary Figure 2), is responsible for
the regulatory effect of TSP-1 on the level of p-Drp1.
HT22 cells were treated with gabapentin, an analog
of γ-aminobutyric acid and a known blocker of the TSP-1-
α2δ1 interaction, to identify the role of the α2δ1
receptor in the action of TSP-1. Interestingly, TSP-1
treatment did not restore the Aβ-induced reduction
of the ratio of p-Drp1 to Drp1 in the gabapentin pre-
treated group (Fig. 5a, b), suggesting that the effect of
TSP-1 on the regulation of the ratio of p-Drp1 to Drp1 is
through the α2δ1 receptor. Together, these data indicate
that TSP-1 attenuates mitochondrial fission, mitochon-
drial dysfunction, and reduced neuronal cell viability
caused by Aβ toxicity mainly through the α2δ1 receptor in
HT22 cells.
Discussion
In this study, we found that TSP-1 has a protective role
in Aβ-induced mitochondrial fission, mitochondrial dys-
function, and neuronal cell death (Supplementary
Figure 3). As a mechanistic link, we identified that TSP-1
maintains the level of p-Drp1 (Ser637), which on the
molecular level is important for maintaining mitochon-
drial dynamics. By blocking the reduction of the p-Drp1
to Drp1 ratio in the presence of Aβ, TSP-1 contributes to
maintaining mitochondrial dynamics and mitochondrial
functions, which is crucial for neuronal cell viability.
Finally, we observed that the protective role of TSP-1
mitigating Aβ-induced mitochondrial dysfunction may be
mediated by the neuronal TSP-1 receptor, α2δ1.
Previous reports show that Aβ induces synaptic dys-
function and mitochondrial impairment19,20. In addition,
it is known that synaptic deficit is closely associated with
mitochondrial dysfunction21. For example, damaged
mitochondria are accumulated in the neuronal cell body
of AD patients’ postmortem brains23. In line with this
report, impaired mitochondrial trafficking and synaptic
deficit due to Aβ treatment have been identified in hip-
pocampal neurons25. Furthermore, there is a report
showing accumulated Aβ and decreased energy metabo-
lism in the synaptosomal mitochondrial fraction of AD
transgenic mice, indicating that Aβ may be a crucial
causative factor in mitochondrial dysfunction and sub-
sequent synaptic deficit and loss26.
TSPs are typical oligomeric matrix proteins and are
primarily secreted from astrocytes to neurons in CNS.
The TSP family members are subdivided according to
their organization and domain structure. TSP-1 and TSP-
2 proteins form trimers, whereas TSP-3, TSP-4, and TSP-
5 proteins form pentamers12. TSPs play main roles in
synaptogenesis, cell migration, and angiogenesis11.
Recently, there have been many reports focusing on the
synaptogenic activity of TSP-1. Son et al.18 showed that
among the isoforms, only TSP-1 was downregulated in
AD brains along with synaptic deficit. In addition,
recovery of the normal level of TSP-1 by treatment with
recombinant TSP-1 protein could attenuate Aβ-induced
dendritic spine loss and synaptic dysfunction in vitro and
(see figure on previous page)
Fig. 2 TSP-1 prevents Aβ-mediated mitochondrial dysfunction in HT22 cells. a HT22 cells were stained with DCFDA dye to measure cellular ROS
levels. b TSP-1 completely blocked Aβ-mediated ROS increase. Data were obtained from at least five replicates for each group. Data are presented as
mean ± SEM. *p < 0.05 vs. vehicle (DMSO)-treated cells; #p < 0.05 vs. Aβ-treated cells. Scale bar, 50 μm. c MitoSOX reagent was used to detect
mitochondrial specific ROS levels. d TSP-1 significantly inhibited Aβ-induced ROS increment. Data were obtained from at least five replicates for each
group. Data are presented as mean ± SEM. **p < 0.01 vs. vehicle (DMSO)-treated cells; ##p < 0.01 vs. Aβ-treated cells. Scale bar, 50 μm. e–i Seahorse
assay using XF analyzer was performed to measure oxygen consumption rate (OCR) after both Aβ only and Aβ + TSP-1 treatment. In addition, basal
respiration, ATP production, the maximal capacity of the OXPHOS system, and non-mitochondrial respiration were also measured by calculating the
change of the OCR value by oligomycin, FCCP, rotenone, and antimycin A administration, with a seahorse XF analyzer. Data were obtained from at
least nine replicates for each group for three independent experiments. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. Aβ-
treated cells
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in vivo, implying a possible role for TSP-1 in AD ther-
apeutics18. However, the effect of TSP-1 in mitochondrial
morphology and function that are critical for AD patho-
logical mechanisms, have not been investigated yet. In this
study, we found that TSP-1 inhibits Aβ-induced disrup-
tion of mitochondrial morphology and dysfunction, by
maintaining the p-Drp1 (Ser637) to Drp1 ratio at a level
similar to that observed in the normal control group via
the α2δ1 neuronal TSP-1 receptor. Together with the
previous results from the study of Son et al. study18, these
data indicate that TSP-1 is a potential therapeutic can-
didate for AD not only because of its protective role in
synaptic deficit but also because of its role in balancing
mitochondrial dynamics and maintaining mitochondrial
functions.
Not surprisingly, mitochondrial function is important
for cell viability owing to its various roles, including ATP
production through OXPHOS, conduction of signals via
second messengers, and regulation of intrinsic apoptosis4.
In addition, mitochondria are highly dynamic organelles
that undergo fragmentation, elongation, trafficking for
ATP supply, and autophagy-mediated mitochondrial
degradation. Thus, balanced mitochondrial dynamics is
crucial for maintaining mitochondrial functions. Mito-
chondrial fission/fusion is one of the major factors con-
trolling mitochondrial quality5. Increasing evidence has
revealed that Aβ increases mitochondrial fission, disturbs
axonal transport, and increases synaptic degeneration, all
of which are mediated by mechanisms related to the Drp1
protein10. Moreover, a recent study has revealed that
inhibiting the activity of Drp1 ameliorates synaptic
depression, Aβ deposition, and cognitive impairment in
AD mice32. Drp1 is a key regulatory protein of mito-
chondrial fission, and PTM of Drp1 is important to its
Fig. 3 TSP-1 recovers neuronal cell viability against Aβ toxicity in HT22 cells and primary hippocampal neurons. TSP-1 plays a protective role
with regards to cell viability against Aβ toxicity. Aβ-mediated cell death in HT22 cells was completely blocked by TSP-1 treatment in a MTT and b
Calcein-AM assays. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 vs. vehicle (DMSO)-treated cells; #p < 0.05, ##p < 0.01 vs. Aβ-treated cells. c
To visually confirm the protective effect of TSP-1 on cell viability, TUNEL assay was performed in the rat primary hippocampal neurons. TSP-1
treatment considerably decreased DNA fragmentation (shown as brown or black dots) in Aβ-treated primary neurons. Scale bar, 20 μm
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GTPase activity29. Within the diverse PTMs of Drp1, we
were interested in phosphorylation of Ser637 residue by
reason of its importance in both mitochondrial fission and
apoptosis30. Besides, pSer637 Drp1 exists in the cytosol,
while the dephosphorylation of Ser637 leads to the
translocation of Drp1 into the mitochondria to start
mitochondrial fragmentation30. To clarify our hypothesis
about the regulatory role of TSP-1 in maintaining the
ratio of p-Drp1 to Drp1 in detail, we performed a western
blot assay. Surprisingly, Aβ-induced reduction in the p-
Drp1 to Drp1 ratio was significantly recovered in the TSP-
1-treated group in HT22 cells (Fig. 4).
Fig. 4 TSP-1 restores the Aβ-induced decrease of p-Drp1 to Drp1 ratio. a In HT22 cells, mitochondrial fission/fusion-related protein levels were
determined by WB under Aβ- and/or TSP-1-treated condition. b–e Phospho-Drp1 (Ser637) to Drp1 ratio, which is important for mitochondrial
dynamics was recovered by TSP-1 against Aβ toxicity while other fusion/fission proteins such as Mfn1, OPA1, and Fis1 were not changed. Data are
presented as mean ± SEM. *p < 0.05, ***p < 0.001 vs. Aβ-treated cells; n.s. means statistically nonsignificant. Data were obtained from at least five
replicates
Fig. 5 α2δ1 receptor is important to mediate the regulating effect of TSP-1 for the ratio of pDrp-1 to Drp1. a, b Gabapentin (100 μM), a
blocker for TSP-1-α2δ1 interaction, suppressed the ability of TSP-1 to maintain p-Drp1 levels. Data are presented as mean ± SEM. ***p < 0.001 vs. Veh
(DMSO)-treated cells; ##p < 0.01 vs. Aβ-treated cells; &&&p < 0.001 vs. GBP + TSP-1-treated cells; n.s. means statistically nonsignificant. Data were
obtained from at least five replicates
Kang et al. Cell Death Discovery  (2018) 4:31 Page 8 of 12
Official journal of the Cell Death Differentiation Association
What is the mechanism underlying the regulation of the
p-Drp1 to Drp1 ratio by TSP-1? To solve this question, we
paid attention to its receptors. TSP-1 has several recep-
tors, including CD47, NL1, and α2δ131. Owing to the
known function of the TSP-1-α2δ1 interaction in the
recovery of spinal loss and synaptic deficit in the AD
condition18, as well as in synaptogenesis in the CNS14, we
postulated that the neuronal α2δ1 receptor may be one of
the most important receptors of TSP-1 in AD. To inves-
tigate whether TSP-1 acts through the α2δ1 receptor to
exert its protective role against Aβ toxicity in mitochon-
dria, we treated HT22 cells with gabapentin, a commonly
prescribed anti-epileptic and anti-neuropathic medica-
tion. Gabapentin completely blocked the ability of TSP-1
to maintain the level of p-Drp1 (Ser637), which resulted
in mitochondrial fission, mitochondrial dysfunction, and
reduced cell viability in the presence of Aβ (Fig. 5). The
α2δ1 receptor is a subunit of a VGCC, thus, the blocking
effect of gabapentin against TSP-1 may be as a result of
the functional modulation of the α2δ1 receptor as a cal-
cium channel component. Gabapentin has a high affinity
for the α2δ1 receptor33 but has been known to block the
TSP-1-α2δ1 interaction without changing calcium chan-
nel expression, function, and kinetics14. Furthermore, the
fact that α2δ1 has the VWF-A-like domain14,15 suggests
that α2δ1 can interact with various types of protein
ligands affecting a wide variety of signaling pathways
independent of calcium signaling. Our data also showed
that treatment of HT22 cells with TSP-1 did not rescue
Aβ-induced intracellular Ca2+ increment, implying that
the effect of TSP-1 in AD might not be dependent on the
modulation of intracellular Ca2+ levels (Supplementary
Figure 2). In addition, Garcia et al.34 reported a novel role
for α2δ1 in myoblast attachment and extracellular sig-
naling, which are not relevant to the calcium signaling
pathway. Furthermore, Eroglu et al.14 also reported the
calcium channel-independent synaptogenic effect of the
TSP-1-α2δ1 interaction in neuronal cells. Therefore,
based on our experimental data, it is highly possible that
the TSP-1-α2δ1 interaction in our study may exert a
protective role against Aβ toxicity via a calcium channel-
independent mechanism, by affecting the regulation of p-
Drp1 (Ser637) levels. We think that there may be down-
stream molecules that regulate the p-Drp1 to Drp1 ratio
under the TSP-1-α2δ1 interaction. Further studies to
determine the molecule responsible for regulating this
process is required.
Thus, TSP-1 may be a potential therapeutic target in
treating AD pathology by inhibiting mitochondrial dys-
function and the disruption of mitochondrial morphology.
Despite the fact that there are 10 times more glial cells
than neurons35, there have not been many studies inves-
tigating the roles of these cell types in the CNS and in
neurodegenerative diseases. Since glial cells secrete many
types of growth factors, neurotrophic factors, and cyto-
kines, their role in the CNS environment appear to be
critical for neuronal survival. Thus, further studies of
secretory molecules, such as TSP-1, from glial cells are
required to identify clinically effective therapeutics in
many CNS disorders by improving the general CNS
environment in which the neuron can maintain cellular
viability consistently.
In conclusion, this study provides evidence that TSP-1
plays a protective role in mitochondrial dynamics, mito-
chondrial function, and neuronal cell viability through its
neuronal receptor α2δ1 (Supplementary Figure 3).
Although the precise mechanism of the TSP-1-α2δ1
interaction affecting mitochondrial dynamics is not well
understood, future research focusing on the protective
role of TSP-1 may reveal a potential therapeutic target for
AD treatment.
Materials and methods
Cell cultures and drug treatment
An immortalized mouse hippocampal neuronal cell line,
HT22, and rat hippocampal primary neurons were used in
this research. HT22 cells were cultured in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum, and
0.1mg/ml of penicillin and streptomycin (P/S; Sigma-
Aldrich, St. Louis, MO, USA) at 37 °C, under 5% CO2 air.
HT22 cells were counted and seeded onto 6-well plates
(1.0× 105 cells/well), 12-well plates (3.0× 104 cells/well),
and seahorse assay plates (1.5× 104 cells/well). Primary
hippocampal neurons were cultured from Sprague-Dawley
rat embryos, as previously described18. The neurobasal
medium with B27 supplement (Invitrogen, Carlsbad, CA,
USA), L-glutamine (0.5mM), and 0.1mg/ml P/S (Sigma-
Aldrich) was used to culture primary neurons and changed
every 2 days. The experiments were executed in cultures at
21 days in vitro. Cells were grown to 70% confluency and
treated solely with 500 ng/ml of human recombinant TSP-1
(R&D System, Minneapolis, MN) for 24 h, or pretreated for
1 h and then co-treated with Aβ (1 μM; American Peptide)
for the remaining 23 h of incubation. Other drugs used in
this study were gabapentin (100 μM; Sigma-Aldrich), oli-
gomycin (2 μM; Seahorse Bioscience, Billerica, MA), car-
bonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP) (2 μM; Seahorse Bioscience), rotenone (0.5 μM;
Seahorse Bioscience), and antimycin A (0.5 μM; Seahorse
Bioscience).
Western blot analysis
Cells were analyzed by western blotting using 4–12%
SDS gradient gels (Invitrogen). The antibodies for the
western blot analysis were as follows: anti-Drp1 (1:2000;
Santa Cruz); anti-p-Drp1 (S637) (1:2000, Cell Signaling
Technology, Beverly, MA, USA); anti-Mfn1 (1:1500; Santa
Cruz); anti-OPA1 (1:500; Santa Cruz); anti-Fis1 (1:1000;
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Santa Cruz); anti-α2δ1 (1:1000, Santa Cruz); anti-β-actin
(1:2000; Sigma-Aldrich); and anti-GAPDH (1:4000;
Sigma-Aldrich). Immunoreactivity was analyzed by
chemiluminescence (GE Healthcare, Piscataway,
NJ, USA). The chemiluminescence signal was observed
with a digital image analyzer (LAS-3000; Fuji Film Inc.,
Tokyo, Japan).
Mitochondria morphology analysis
Mitochondrial morphology was investigated using
MitoTracker Green FM (Thermo Fischer Scientific,
Hudson, NH, USA) in drug-treated HT22 cells. Briefly,
cells were pretreated with 500 ng/ml TSP-1 recombinant
protein for 1 h and 1 μM Aβ or DMSO was additionally
administered to the cells for next 23 h. Next, cells were
stained with 100 nM MitoTracker Green FM for 20 min
to visualize mitochondrial morphology and then washed
two times with Opti-MEM. Live-cell imaging was taken
using the confocal laser scanning microscope (FV10i-w,
Olympus, Tokyo, Japan) and analyzed using the Image J
program (NIH, Bethesda, MD, USA). To quantify the
change in mitochondrial morphology in detail, the cells
were also observed using EM as previously described36.
HT22 cells were fixed with an EM-fixative solution of
cold 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH
7.2) and 2% paraformaldehyde in 0.1 M phosphate or
cacodylate buffer (pH 7.2) overnight and embedded in
epoxy resin. Epoxy resin-embedded samples were loaded
into capsules and allowed to form polymers (38 °C for 12
h and 60 °C for 48 h). Sliced sections were cut using an
ultramicrotome (RMC MT-XL) and collected on a grid
made of copper. Appropriate areas from thin sectioning
were cut at 65 nm and stained with saturated 4% uranyl
acetate and 4% lead citrate, and then examined with a
transmission electron microscope (JEM-1400; Tokyo,
Japan) at 80 kV. Mitochondrial length, damaged mito-
chondrial fraction per cell, and total mitochondrial
number per cell were quantified manually. Seven cells
per group were analyzed for two independent
experiments.
Intracellular and mitochondrial ROS level measurement
To detect intracellular ROS levels, cells were incubated
with 1 μM dichlorofluorescein diacetate (Invitrogen) for
30min and washed with warm phosphate-buffered saline
(PBS). Mitochondria-specific ROS were detected using
MitoSOX Red (5 μM for 15 min at 37 °C) following the
manufacturer’s protocols (Invitrogen). For all mitochon-
drial assays, cells were treated with vehicle, 1 μM Aβ, or
500 ng/ml TSP-1 for 24 h, or pretreated with TSP-1 for 1
h and co-incubated with either 1 μM Aβ or DMSO for the
next 23 h. Fluorescent signals were captured using a
fluorescence microscope (Olympus), and >100 cells were
analyzed for each group.
Measurements of OCR
A Seahorse Bioscience XF24–3 extracellular flux ana-
lyzer (Seahorse Bioscience) was used to detect OCR when
glucose, L-glutamine, and sodium pyruvate (Sigma-
Aldrich) were added to Seahorse XF base medium (Sea-
horse Bioscience) surrounding HT22 cells. Cells were
cultured in XF24 V7 cell culture microplates according to
the manufacturer’s instructions. Briefly, OCR measure-
ments were performed after equilibration of calibration
medium (Seahorse Bioscience). Every 4 min, the O2 con-
centration was measured. OCR was recorded as a unit of
pmol/min. Baseline rates were first measured. Then,
preloaded oligomycin (2 μM; Seahorse Bioscience), FCCP
(2 μM; Seahorse Bioscience), rotenone (0.5 μM: Seahorse
Bioscience), and antimycin A (0.5 μM; Seahorse
Bioscience) were injected in a consecutive order into each
well of the cell plate in a calibration chamber during the
Seahorse assay. After mixing the injected drugs and assay
medium for 2 min, OCR was measured four to six times.
The averages of five baseline rates and four to five test
rates were used for data analyses.
Live and dead cell assay
Calcein-AM assay
To measure cell viability, the calcein-AM assay was
performed. Briefly, 5× 103 cells were incubated for 24 h
after seeding in a 96-well plate, and then treated with Aβ
and/or Tsp-1 for 24 h. Calcein-AM reagent (C3099,
Molecular Probes, Invitrogen) in phenol red-free media
(1M) was added, incubated for 1 h at 37 °C, and washed
three times with PBS. Fluorescence was measured at
excitation and emission wavelengths (ex/em) of 485 nm/
530 nm on a fluorescence plate reader (Infinite M200 Pro;
TECAN, Mannendorf, Switzerland).
MTT assay
For measuring the activities of mitochondrial enzymes,
MTT assays were performed37. Briefly, 2.5 mg/ml MTT
(M2003; Sigma-Aldrich) in phenol red-free medium was
added to the cells and incubated for 2 h at 37 °C, followed
by the aspiration of the MTT solution, and the addition of
isopropanol, which was incubated at 37 °C for 1 h to
dissolve formazan crystals. Absorbance was measured at
540 nm. Experiments were repeated at least three times
independently, and data were expressed as a percentage of
the control cell.
TUNEL assay
The TUNEL assay was performed with a DeadEnd
Colorimetric TUNEL System (Promega, Madison, WI,
USA) according to the manufacturer’s instructions in rat
primary hippocampal neurons.
For all cell viability and cell death assays, cells were
treated with vehicle, 1 μM Aβ, or 500 ng/ml of TSP-1 for
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24 h, or pretreated with TSP-1 for 1 h and co-incubated
with 1 μM Aβ or DMSO for next 23 h.
Intracellular calcium measurement
To measure intracellular calcium levels, Fluo-4 Direct™
Calcium Assay (Thermo Fischer Scientific) was performed
following the manufacturer’s protocols. Briefly, 50 μl of
the 2× Fluo-4 Direct™ calcium reagent loading solution
was added to each well of a 96-well plate containing 50 μl
of growth medium. The plate was then incubated at 37 °C
for 30 min, followed by an additional 30 min incubation
period at room temperature. Fluorescent signals were
then measured using a fluorescence microscope. The
intensity of the results was analyzed with the Image J
program for three independent experiments.
Data analysis and statistics
For western blot analysis, protein levels were normal-
ized to pan forms or housekeeping proteins, such as β-
actin or GAPDH. All data were expressed as means±
SEM). Statistical analysis was performed using GraphPad
Prism 5. The data were analyzed by one-way analysis of
variance with post hoc test (*p< 0.05, **p< 0.01, and ***p
< 0.001).
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